Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study

View Full Paper
Ask AI
Bookmark
Share

Authors

CFCécile FavreauGVGeoffroy VentonMLMichaël Loschi

Discussion

Loading...

Member takes

Overview

Observational analysis linked venetoclax efficacy to BCL-2 expression and BH3 profiling in AML patients, suggesting improved outcomes.

Key Points

  • The treatment response improved with higher BCL-2 expression in patients, highlighting its predictive role.
  • After two cycles, the complete remission rate was 35% in acute myeloid leukemia patients treated with azacitidine plus venetoclax.
  • Analysis included various prognostic models, assessing plasma level variabilities and apoptosis markers in 20 patients.
  • Identifying genetic mutations such as Mcl-1 and Bcl-xL was crucial for understanding individual responses to treatment.

Cite This Study

Favreau et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e044https://doi.org/10.1182/blood-2025-5250
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial2025
  2. 2Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia2025
  3. 3Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  4. 4A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes2025 · 1 citations
  5. 5IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025